# Contact Semaglutide Legit: Editorial Correspondence

> Contact Semaglutide Legit, an independent editorial digest of the semaglutide research literature. Editorial correspondence only — not a clinic, not a vendor, no medical advice.

Corrections, sources, and questions about the published record.

## Reaching the editors

Semaglutide Legit welcomes editorial correspondence — corrections to the record, suggestions of peer-reviewed studies we have missed, and questions about how a particular claim on this site is sourced. Because this is a documentation project, the most useful messages point to a specific page and a specific citation. Use the form below to send a note; an email-style reply address is the only contact channel we maintain.

We cannot answer personal medical questions, and we will not. This site does not provide medical advice, diagnose, or recommend treatment, and no message sent here creates a clinician-patient relationship. For any decision about your own health or medication, please consult a qualified healthcare professional.

## Send a message

Please include your name, an email address for a reply, and your message. For corrections, naming the page and the reference number helps us verify quickly against the source.

- **Name** — so we know who we are corresponding with.
- **Email** — a reply address; we use it only to respond.
- **Message** — your correction, source suggestion, or question about the published record.

This form is for editorial correspondence about the research literature only. It is not a channel for medical advice, prescriptions, or product enquiries.

---

A documentation-grade reading of the semaglutide trial record — STEP, SUSTAIN, SELECT, FLOW, and the 2025 ESSENCE liver data — each finding versioned to its source and the approved-versus-compounded line drawn in full, by a publisher that prescribes nothing and sells nothing.